We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

EMA permits the use of a comparator product authorised outside the EEA in clinical studies for biosimilars

April 2015

Focus on Regulation - Hogan Lovells Blog

The European Medicines Agency’s (“EMA”) revised overarching guideline on biosimilars (“Guideline”), which was published on 23 October 2014, will come into force on 30 April 2015.

Click here to read more.

The team

Loading data